# GOVX earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/GOVX) · [Earnings tab](https://www.lopjlb.com/stock/GOVX?tab=earnings)

Updated: 2026-07-27T07:29:19

Quarters analyzed: 8

## Cross-quarter narrative

Across the earnings calls, GeoVax's tone and guidance evolved, with management tone increasing from 0.00 to 0.70 before returning to 0.00. The company reported progress on its BARDA Project NextGen award, advanced cGMP seed production for GEO-MVA, and outlined Phase 2 plans for Gedeptin and CM04S1. However, funding needs, regulatory uncertainties, and manufacturing risks persisted. Demand for immunocompromised COVID-19 and Mpox vaccines remained strong, with BARDA awards and financing supporting the company's programs.

## Latest CallCard · Q3

GeoVax advances GEO-MVA (Mpox/smallpox) with EMA expedited path, GEO-CM04S1 for immunocompromised COVID-19, and Gedeptin for head/neck cancer; cash $5M, exploring partnerships/nondilutive funding.','tone':{'mgmt':0.3,'mgmt_rationale':'Prepared remarks emphasize confidence in portfolio progress, expe

**Guidance:** vague

**Tone:** mgmt 0 · Q&A pressure 0 · divergence 0

## Quarter one-liners

- **2025 Q3:** GeoVax advances GEO-MVA (Mpox/smallpox) with EMA expedited path, GEO-CM04S1 for immunocompromised COVID-19, and Gedeptin for head/neck cancer; cash $5M, exploring partnerships/nondilutive funding.','tone':{'mgmt':0.3,'mgmt_rationale':'Prepared remarks emphasize confidence in portfolio progress, expe
- **2025 Q2:** —
- **2025 Q1:** GeoVax Q1 2025: BARDA Project NextGen terminated for convenience (<$750K annual impact); CM04S1 Phase 2 continues in immunocompromised; GEO-MVA cGMP batch released for clinical evaluation; Gedeptin Phase II prep underway; cash $7.4M; exploring partnerships/non-dilutive funding.','tone': {'mgmt': 0.2
- **2024 Q4:** GeoVax reported $4M BARDA revenue, completed cGMP batch for GEO-MVA, and outlined 2025 milestones for its NextGen COVID-19 vaccine, while noting cash constraints and regulatory uncertainties.
- **2024 Q3:** GeoVax reported progress on its BARDA Project NextGen award, advanced cGMP seed production for GEO-MVA, and outlined Phase 2 plans for Gedeptin and CM04S1, while noting funding needs and a lengthy cell‑line qualification timeline.
- **2024 Q1:** GeoVax advances Gedeptin (solid tumors) and CM04S1 (next-gen COVID vaccine) Phase II programs; cash $769K at March 31, expects near-term capital raise; BARDA Project NextGen talks ongoing; MVA smallpox/Mpox vaccine progressing toward regulatory submission. No revenue; net loss $5.6M Q1. Management u
- **2023 Q4:** —
- **2023 Q3:** —

## Theme arcs

- **Management Tone** (deteriorating): Returned to 0.00 after increasing to 0.70
- **Regulatory Progress** (improving): EMA expedited path for GEO-MVA
- **Funding and Capital** (stable): BARDA awards and financing supported programs, but cash constraints remained
- **Manufacturing and Production** (improving): cGMP batch for GEO-MVA completed and AGE-1 process advanced
- **Demand and Market** (stable): Strong demand for immunocompromised COVID-19 and Mpox vaccines persisted

## Fear persistence

- **Financing and Liquidity** [recurring]: Cash constraints and reliance on BARDA awards and financing persisted
- **Regulatory** [recurring]: Uncertainty over trial start dates, possible pauses in vaccine approvals, and FDA interactions remained
- **Manufacturing** [recurring]: Scaling up MVA production and new AGE-1 process may encounter technical challenges
- **Market Competition** [recurring]: Competing vaccines may be more effective or easier to use
- **Demand** [resolved]: Strong demand for immunocompromised COVID-19 and Mpox vaccines remained, but uncertainty over uptake of Mpox vaccine persisted

## Guidance path

2023 Q3:vague → 2023 Q4:vague → 2024 Q1:vague → 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:vague → 2025 Q3:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/GOVX`